Roivant Sciences Ltd. (ROIV)
| Previous close | 10.90 |
| Open | 10.78 |
| Bid | 10.67 x 100 |
| Ask | 10.68 x 100 |
| Day's range | 10.51 - 10.78 |
| 52-week range | 8.06 - 13.24 |
| Volume | |
| Avg. volume | 7,470,490 |
| Market cap | 8.606B |
| Beta (5Y monthly) | 1.34 |
| PE ratio (TTM) | 2.03 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Simply Wall St.
Roivant Sciences Third Quarter 2024 Earnings: Beats Expectations
Roivant Sciences ( NASDAQ:ROIV ) Third Quarter 2024 Results Key Financial Results Revenue: US$37.1m (up 118% from 3Q...
- GuruFocus.com
Roivant Sciences Ltd President & COO Eric Venker Sells 96,950 Shares
Eric Venker, President & COO of Roivant Sciences Ltd (NASDAQ:ROIV), executed a sale of 96,950 shares in the company on February 9, 2024, according to a recent SEC Filing.
- Yahoo Finance Video
Roche acquires Telavant, rights to bowel disease drug
Swiss pharmaceutical company Roche (ROG.SW, RHHBY) acquired Telavant — a Roivant Sciences (ROIV, ROIVW) subsidiary — for $7.1 billion in a deal that will allow the multinational healthcare company to develop a bowel disease drug. Yahoo Finance's Seana Smith and Brad Smith take a closer look at what the deal could mean for Roche as it branches out into more experimental drugs. For more expert insight and the latest market action, click here to watch this full episode of Yahoo Finance Live.
